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approximation of the energy deposited by each individual 
proton in each layer. 
A tracking algorithm is able to find the water equivalent path 
length of each individual proton. When this information is 
combined with the approximated energy deposition on each 
layer, an estimate of the incoming proton energy is obtained 
by locating the high energy deposit of the Bragg Peak. 
Results from this analysis, as well as the capabilities of 
alternative setups will be presented, to show the feasibility 
of using such a calorimeter for proton Computed 
Tomography. 
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Purpose: The more selective energy deposition of protons in 
depth is advantageous compared to photons to preserve 
normal tissues. Nevertheless, an even better tissue sparing 
might be possible in proton therapy if combined with the 
well-established tissue preservation of spatially fractionated 
submillimetric beams. This sparing effect has been observed 
in studies performed with synchrotron minibeam 
radiotherapy (MBRT) [1,2].  
The innovative approach proposed here, called proton 
minbeam radiation therapy (pMBRT), was shown to lead to 
favorable dose distributions in Monte Carlo (MC) studies [3]. 
The dose profiles in normal tissue consist in peaks and 
valleys, while the tumour receives a (quasi)-homogenous 
dose distribution [3]. The goal of this study was to implement 
this promising approach at a clinical center, as well as to 
gather a complete set of dosimetric data that will serve to 
guide the ongoing biological experiments [4].  
Material and Methods: The implementation of pMBRT was 
carried out at the Proton Therapy Center in Orsay (ICPO). 100 
MeV-proton minibeams (400 and 700 μm-width) were 
generated by means of a multislit collimator. The dose 
distributions (depth dose curves, lateral profiles, peak-to-
valley dose ratios (PVDR) [6], beam widths and output 
factors) were measured by means of Gafchromic EBT3 films 
and the new PTW microDiamond detector [5].  
In parallel, a very first MC-based calculation engine for 
pMBRT is under development using Gate v7.0. 
Results: The experimental data confirm that a spatial 
fractionation of the dose is maintained in normal tissues 
(PVDR up to 7) while a quasi-homogeneous dose distribution 
is reached at the Bragg peak location, in agreement with 
theoretical predictions [3]. The reduced penumbras (600-
1100 μm) in healthy tissue make pMBRT a good candidate for 
radiosurgery applications.  
Similar results were obtained using either EBT3 films or the 
PTW microDiamond detector. The preliminary MC 
calculations were consistent with experimental dose 
distributions.  
Conclusion: This is the first work providing both a complete 
set of dosimetric data in such small proton field sizes and a 
practical implementation of this promising approach using a 
clinical set-up and beam energy. The dose distributions 
showed the potential of this technique, which might lead to a 
reduction of the normal tissue complication probability. 
Animal irradiation experiments are ongoing to confirm the 
normal tissue sparing capability of pMBRT. 
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Purpose: We assessed in vitro and in vivo the relative 
contribution of direct and bystander effects in the 
therapeutic efficacy of RIT using 212Pb-labeled mAbs for 
treating cancer cells.  
Materials and Methods: A-431 cells were in vitro exposed to 
increasing activities (0–0.5 MBq/mL; 37 MBq/mg) of either 
35A7 (anti-CEA), Trastuzumab (anti-HER2) or PX (non-
specific) 212Pb-labeled mAbs. The relative contribution of 
direct and bystander effects was determined using standard 
medium transfer protocol. Biological end points included 
clonogenic survival and DNA double strand breaks (using 
53BP1 and gamma-H2AX immunofluorescence detection) 
measured both in donor (direct effect) and in recipient cells 
(bystander effects). In vivo, nude mice with intraperitoneal 
(i.p.) 2-3 mm A-431 tumour cells xenografts were i.p. 
injected with increasing activities (370–1480 kBq; 37 
MBq/mg) of the above mentioned anti-CEA, anti-HER2 or non-
specific 212Pb-mAbs. Tumour growth was determined and the 
distribution of radioactivity at the tissue level was assessed 
using digital micro-autoradiography (DAR) followed by voxel 
dosimetry. Biological markers including 53BP1 and Ki67 
proteins together with abnormal mitosis were also 
determined on tumour sections. 
Results: In vitro we showed in donor cells the strong efficacy 
of 212Pb-35A7 and 212Pb-trastuzumab mAbs and also to a lower 
extent of 212Pb-PX mAb. Significant bystander cytotoxicity 
was measured in all recipient cells with the three 
radiolabeled mAbs. The complexity of DNA damage (53BP1 
foci) observed in donor cells confirmed the high LET 
cytotoxic effects of 212Pb-mAbs while less complex damage 
were observed in recipient cells. 
In vivo DAR and voxel dosimetry indicated the strong 
heterogeneity in anti-CEA 212Pb-mAbs distribution in tumours. 
Conversely, distribution of anti-HER2 212Pb-mAbs was much 
more homogeneous. These data could explain the lower 
therapeutic efficacy of the latter mAbs compared with anti-
HER2 212Pb-mAbs (median survival of 94 days for anti-CEA 
212Pb-mAbs versus 20 days for control, not reached for anti-
HER2 212Pb-mAbs). Moreover, voxel dosimetry indicated that 
about 30% of the tumours of mice treated with anti-CEA 
212Pb-mAbs received 0Gy. However, we also observed in the 
same tumours, homogeneous formation of DNA damage 
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independently of absorbed doses distribution, together with 
abnormal mitosis. The latter results indicate that bystander 
effects could also be involved. However, at this stage, we 
may assume that they do not fully counterbalance the lack of 
efficacy due to heterogeneous distribution of anti-CEA 212Pb-
mAbs, possibly because lesions are not as complex as those 
produced by high LET radiation.  
Conclusions: Our results showed in vitro and in vivo that, 
besides the strong direct effect of 212Pb-labeled mAbs in 
killing tumour cells, bystander effects have also to be 
considered.  
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Radiotherapy is an important treatment modality for millions 
of patients with cancer worldwide. Current treatment 
decisions do not take into account individual patients’ or 
cohorts of patients’ sensitivities to this treatment modality. 
As such, patients treated with radiation therapy experience a 
large variation in normal tissue toxicity that results in dose-
limiting acute and irreversible progressive side effects. 
Important examples of these adverse effects include 
mucositis, pneumonitis, and cognitive damage, respectively 
representing acute, intermediate, and late effects. 
Stratification of patients based on radiation sensitivities will 
allow delivery of suitable alternative treatments to high-risk 
patients and dose escalation to tumors in less sensitive 
patients. Current focus on radiation 
biomarkers/biodosimeters appears to be primarily to assess 
radiation doses after catastrophic accidental radiation 
exposure. Recent advances have brought together several 
cross-disciplinary areas such as biological assays, analytical 
platforms, and algorithms to rapidly assess dose to 
individuals. These technologies are at different maturation 
levels. This immense progress is also an opportunity to use 
them to predict heterogeneity of radiation sensitivities 
among cancer patients to improve radiation therapy outcome 
and their quality of life. This talk will emphasize the need 
for discovery, development, and validation of predictive 
biomarkers, provide some examples of biomarkers, and 
discuss the translational challenges involved in leveraging 
advances in radiation-specific biomarker research to 
radiotherapy, which for the foreseeable future likely to 
remain a cornerstone of cancer treatment.  
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Purpose: Range verification in proton therapy is highly 
desirable to fully exploit the advantageous properties of 
proton beams for tumor therapy. In this context, prompt 
gamma imaging (PGI) is of growing interest and different 
technical concepts for realization are currently under 
investigation. The feasibility of range shift detection with a 
slit camera has previously been shown for different targets 
irradiated with protons in pencil beam scanning mode [1-3]. 
In preparation of the clinical application of the slit camera 
within a patient study, we report on the first application of 
the slit camera to passively shaped proton beams.  
Materials / Methods: Targets with increasing complexity have 
been irradiated with passively shaped proton beams (double 
scattering mode). For artificial range shift induction, the 
energy of the protons was varied. Prompt gamma emission 
was monitored by means of a knife-edge shaped slit camera.  
Prompt gamma rays emitted during the irradiation are 
projected through a slit aperture onto a segmented detector. 
Thus, a one-dimensional depth distribution of detected 
prompt gamma rays is obtained.  
In double scattering mode, a high neutron induced 
background hampers direct range shift evaluation from these 
detected gamma distributions. In order to quantify this 
background, measurements have been repeated with a closed 
slit aperture of the camera. This facilitates a subtraction of 
the background from the measurements with open slit. 
Time resolved analysis of the measurements allows for a 
mapping of single prompt gamma profiles to different steps 
of the range modulator wheel, and, thus, to different iso-
energy layers. 
Results: Global range shifts of several millimeters in 
homogeneous as well as inhomogeneous targets were 
detected with the slit camera measurement during proton 
irradiation with passive field formation. Figure 1 shows the 
experimental setup with a head target (left) and detected 
prompt gamma profiles for different proton energies, i.e. 
different requested proton ranges (right). Separation of 
different prompt gamma profiles related to single steps of 
the range modulator wheel was possible. 
 
 
 
Figure 1: Left: Experimental setup of a prompt gamma slit 
camera measurement during irradiation of a head phantom 
with a passively shaped proton beam. Right: Measured 
prompt gamma depth profiles, normalized to the applied 
monitor units (MU) for different requested proton ranges, i.e. 
different proton energies. 
 
Conclusions: In preparation of the application of the slit 
camera to patient treatment, we investigated the 
detectability of range shifts in double scattering proton 
irradiation. Global range shifts of a few millimeters were 
detected from measurements with the slit camera. Time 
resolved analysis allows for separation of prompt gamma 
profiles correlated to protons of different iso-energy layers. 
This might provide additional information on potential 
sources of range deviations. 
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